Longevity & Aging
a bempedoic-acid prodrug (via PPAR-alpha activation) shifts amyloid precursor protein processing away from the amyloidogenic pathway in Alzheimer's-relevant models
In plain terms: Could the cholesterol drug bempedoic acid, by switching on PPAR-alpha, steer the brain away from making Alzheimer's amyloid?
Part of: 💊 bempedoic acid
Independent mouse and mechanistic work consistently shows PPAR-alpha activation — which bempedoic acid does (Cell Metab 2026) — can steer APP away from the amyloid pathway and boost amyloid clearance, and that pathway evidence is what carries the grade. But no study tests bempedoic acid itself in the brain, so this is a mechanism/animal-grade inference about a plausible repurposing, NOT a demonstrated anti-amyloid effect in people.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
<!-- vault-context --> Norwitz **affirms** this claim. Consensus below reflects independent literature only.
The evidence (8)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Combs 2001 · J Neurosci | in-vitro | mixed | moderate | PPARalpha agonists suppress Abeta-stimulated proinflammatory gene expression in monocytes but fail to block neurotoxic-factor release. |
| Raha 2021 · Sci Signal | animal | supports | moderate | PPARalpha activation enhances astroglial LDLR/TFEB-mediated uptake and lysosomal degradation of Abeta, lowering brain amyloid burden in 5XFAD mice. |
| Luo 2020 · Autophagy | animal | supports | moderate | PPARalpha agonists (gemfibrozil, Wy14643) induce autophagy and reduce soluble/insoluble Abeta and cognitive deficits in APP-PSEN1 mice. |
| Corbett 2015 · Proc Natl Acad Sci U S A | animal | supports | high | Independent mechanism: PPARalpha activation stimulates ADAM10-mediated alpha-secretase cleavage of APP (non-amyloidogenic), reducing Abeta in mice. Supports pathway plausibility, not bempedoic specifically. |
| 2024 venue: Neurol Res · Neurol Res | animal | supports | low | PPARalpha/gamma dual agonist attenuates AD molecular pathology in model; supportive of class effect, not bempedoic. |
| 2023 venue: Brain Behav Immun · Brain Behav Immun | animal | supports | moderate | Exercise activates hippocampal PPARalpha -> upregulates ADAM10, decreases plaques & improves cognition in AD mice; corroborates PPARalpha->ADAM10->non-amyloidogenic axis. |
| Comerota 2023 · Mol Neurodegener | animal | supports | moderate | PPARalpha/TFEB agonist OEA analog attenuates Abeta pathology and neuroinflammation in an Alzheimer mouse model. |
| 2026 venue: Cell Metab · Cell Metab | mechanism | mixed | high | Verified cited paper: bempedoic acid directly binds & activates PPARalpha (X-ray + hepatocyte/liver FAO). Confirms PPARalpha activation ONLY; paper is about hepatic fatty-acid oxidation, NOT APP/amyloid. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.